NO317648B1 - Fremgangsmate for fremstilling av HIV proteaseinhibitorer - Google Patents
Fremgangsmate for fremstilling av HIV proteaseinhibitorer Download PDFInfo
- Publication number
- NO317648B1 NO317648B1 NO20004664A NO20004664A NO317648B1 NO 317648 B1 NO317648 B1 NO 317648B1 NO 20004664 A NO20004664 A NO 20004664A NO 20004664 A NO20004664 A NO 20004664A NO 317648 B1 NO317648 B1 NO 317648B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- carried out
- reacting
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 230000008569 process Effects 0.000 title claims description 6
- 239000004030 hiv protease inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- -1 p-nitrophenylsulfonyl group Chemical group 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 claims description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 3
- AUYHZFAGBOOPMD-CMXBXVFLSA-N n-[(2r,3s)-3-amino-2-hydroxy-4-phenylbutyl]-n-(2-methylpropyl)-4-nitrobenzenesulfonamide;hydrochloride Chemical group Cl.C([C@H](N)[C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 AUYHZFAGBOOPMD-CMXBXVFLSA-N 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229940075894 denatured ethanol Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- NVEPLQDORJSXRO-DLBZAZTESA-N tert-butyl n-[(2s,3r)-3-hydroxy-4-(2-methylpropylamino)-1-phenylbutan-2-yl]carbamate Chemical compound CC(C)CNC[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 NVEPLQDORJSXRO-DLBZAZTESA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical group OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- IUFITGQVUSROFE-QMMMGPOBSA-N [(2s)-2-imidazol-1-yloxolan-2-yl] carbamate Chemical compound C1=CN=CN1[C@@]1(OC(=O)N)CCCO1 IUFITGQVUSROFE-QMMMGPOBSA-N 0.000 description 1
- ZMNCIAGFQBUWTJ-OEMFJLHTSA-N [(3s)-oxolan-3-yl] n-[(2s,3r)-3-hydroxy-4-[2-methylpropyl-(4-nitrophenyl)sulfonylamino]-1-phenylbutan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 ZMNCIAGFQBUWTJ-OEMFJLHTSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9805898.5A GB9805898D0 (en) | 1998-03-20 | 1998-03-20 | Process for the sythesis of hiv protease inhibitors |
| PCT/GB1999/000852 WO1999048885A1 (en) | 1998-03-20 | 1999-03-18 | Process for the synthesis of hiv protease inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004664D0 NO20004664D0 (no) | 2000-09-19 |
| NO20004664L NO20004664L (no) | 2000-09-19 |
| NO317648B1 true NO317648B1 (no) | 2004-11-29 |
Family
ID=10828884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004664A NO317648B1 (no) | 1998-03-20 | 2000-09-19 | Fremgangsmate for fremstilling av HIV proteaseinhibitorer |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6281367B1 (cs) |
| EP (1) | EP1066276B1 (cs) |
| JP (1) | JP3363439B2 (cs) |
| KR (1) | KR100555278B1 (cs) |
| CN (1) | CN1308319C (cs) |
| AP (1) | AP1226A (cs) |
| AT (1) | ATE242772T1 (cs) |
| AU (1) | AU751534B2 (cs) |
| BR (1) | BR9908970A (cs) |
| CA (1) | CA2324217C (cs) |
| CZ (1) | CZ299193B6 (cs) |
| DE (1) | DE69908761T2 (cs) |
| DK (1) | DK1066276T3 (cs) |
| EA (1) | EA003022B1 (cs) |
| EE (1) | EE04750B1 (cs) |
| ES (1) | ES2203090T3 (cs) |
| GB (1) | GB9805898D0 (cs) |
| HR (1) | HRP20000609B1 (cs) |
| HU (1) | HUP0105439A3 (cs) |
| ID (1) | ID26587A (cs) |
| IL (1) | IL138127A (cs) |
| IS (1) | IS2273B (cs) |
| NO (1) | NO317648B1 (cs) |
| NZ (1) | NZ506563A (cs) |
| PL (1) | PL201810B1 (cs) |
| PT (1) | PT1066276E (cs) |
| RS (1) | RS49954B (cs) |
| SK (1) | SK283939B6 (cs) |
| TR (1) | TR200002698T2 (cs) |
| WO (1) | WO1999048885A1 (cs) |
| ZA (1) | ZA200004482B (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2140929C (en) | 1992-08-25 | 2006-09-12 | Michael L. Vazquez | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| DE60039533D1 (de) * | 1999-12-23 | 2008-08-28 | Ampac Fine Chemicals Llc | Verbessertes verfahren zur herstellung von 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin |
| US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| WO2003106461A2 (en) | 2002-05-16 | 2003-12-24 | Tibotec Pharmaceuticals Ltd | Pseudopolymorphic forms of a hiv protease inhibitor |
| US7772411B2 (en) | 2003-12-23 | 2010-08-10 | Tibotec Pharmaceuticals Ltd. | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
| DE602004021640D1 (de) * | 2003-12-23 | 2009-07-30 | Tibotec Pharm Ltd | Verfahren zur herstellung von (1s,2r)-3-ää(4-aminophenyl)sulfonylü(isobutyl)aminoü-1-benzyl-2-hydroxypropylcarbamidsäure-(3r,3as,6ar)-hexahydrofuroä2,3-büfuran-3-ylester |
| AR073248A1 (es) | 2008-09-01 | 2010-10-20 | Tibotec Pharm Ltd | Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso. |
| SMT201800290T1 (it) | 2010-01-27 | 2018-07-17 | Viiv Healthcare Co | Terapia antivirale |
| WO2012032389A2 (en) | 2010-09-10 | 2012-03-15 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
| CN111233794A (zh) * | 2020-03-27 | 2020-06-05 | 江巨东 | 一种安普那韦的精制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1071930A (zh) * | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂 |
| CA2140929C (en) * | 1992-08-25 | 2006-09-12 | Michael L. Vazquez | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
-
1998
- 1998-03-20 GB GBGB9805898.5A patent/GB9805898D0/en not_active Ceased
-
1999
- 1999-03-18 WO PCT/GB1999/000852 patent/WO1999048885A1/en not_active Ceased
- 1999-03-18 NZ NZ506563A patent/NZ506563A/en unknown
- 1999-03-18 EA EA200000859A patent/EA003022B1/ru unknown
- 1999-03-18 DK DK99910543T patent/DK1066276T3/da active
- 1999-03-18 KR KR1020007010359A patent/KR100555278B1/ko not_active Expired - Fee Related
- 1999-03-18 IL IL13812799A patent/IL138127A/xx not_active IP Right Cessation
- 1999-03-18 RS YUP-559/00A patent/RS49954B/sr unknown
- 1999-03-18 US US09/646,277 patent/US6281367B1/en not_active Expired - Lifetime
- 1999-03-18 PL PL342602A patent/PL201810B1/pl not_active IP Right Cessation
- 1999-03-18 DE DE69908761T patent/DE69908761T2/de not_active Expired - Lifetime
- 1999-03-18 CA CA002324217A patent/CA2324217C/en not_active Expired - Fee Related
- 1999-03-18 HU HU0105439A patent/HUP0105439A3/hu unknown
- 1999-03-18 PT PT99910543T patent/PT1066276E/pt unknown
- 1999-03-18 EE EEP200000568A patent/EE04750B1/xx not_active IP Right Cessation
- 1999-03-18 SK SK1373-2000A patent/SK283939B6/sk not_active IP Right Cessation
- 1999-03-18 HR HR20000609A patent/HRP20000609B1/xx not_active IP Right Cessation
- 1999-03-18 EP EP99910543A patent/EP1066276B1/en not_active Expired - Lifetime
- 1999-03-18 JP JP2000537868A patent/JP3363439B2/ja not_active Expired - Lifetime
- 1999-03-18 TR TR2000/02698T patent/TR200002698T2/xx unknown
- 1999-03-18 CN CNB998042242A patent/CN1308319C/zh not_active Expired - Fee Related
- 1999-03-18 ES ES99910543T patent/ES2203090T3/es not_active Expired - Lifetime
- 1999-03-18 AU AU29475/99A patent/AU751534B2/en not_active Ceased
- 1999-03-18 ID IDW20001857A patent/ID26587A/id unknown
- 1999-03-18 BR BR9908970-0A patent/BR9908970A/pt not_active Application Discontinuation
- 1999-03-18 CZ CZ20003457A patent/CZ299193B6/cs not_active IP Right Cessation
- 1999-03-18 AP APAP/P/2000/001911A patent/AP1226A/en active
- 1999-03-18 AT AT99910543T patent/ATE242772T1/de not_active IP Right Cessation
-
2000
- 2000-08-29 ZA ZA200004482A patent/ZA200004482B/en unknown
- 2000-08-29 IS IS5605A patent/IS2273B/is unknown
- 2000-09-19 NO NO20004664A patent/NO317648B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS55900B1 (sr) | Fermentisana mešavina na bazi soje koja obuhvata izoflavone-aglikone, equol i lunasil, postupak za pripremanje i njene upotrebe u prehrambenim, medicinskim i kozmetičkim oblastima | |
| JP6811717B2 (ja) | トピロキソスタット及びその中間体の調製のための方法 | |
| NO317648B1 (no) | Fremgangsmate for fremstilling av HIV proteaseinhibitorer | |
| JP6454707B2 (ja) | ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成 | |
| CN112272665B (zh) | 制备立他司特的方法 | |
| CA1089473A (en) | Process for the production of 3-amino-isoxazoles | |
| MXPA00008925A (en) | Process for the synthesis of hiv protease inhibitors | |
| RU2761167C1 (ru) | Способ получения картолина-2 | |
| HK1032047B (en) | Process for the synthesis of hiv protease inhibitors | |
| RU2775690C2 (ru) | Синтез транс-8-хлор-5-метил-1-[4-(пиридин-2-илокси)-циклогексил]-5,6-дигидро-4н-2,3,5,10в-тетраазабензо[e]азулена и его кристаллические формы | |
| JP3997440B2 (ja) | アシルイソシアネートの製造方法 | |
| CN119768406A (zh) | 用于取代的吡咯并嘧啶和中间体的制备的方法 | |
| JP3370520B2 (ja) | 一置換ニトログアニジン類の製造法 | |
| CN111164071A (zh) | 用于合成药物的中间体化合物的制备方法 | |
| JPS63246369A (ja) | ２，３−ジオキソピペラジン類の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |